Sacrosidase
Brand name: Sucraid
Rank #437 of 500 drugs by total cost
$18.5M
Total Cost
1,517
Total Claims
$18.5M
Total Cost
70
Prescribers
$12K
Cost per Claim
106
Beneficiaries
1,565
30-Day Fills
$264K
Avg Cost/Provider
22
Avg Claims/Provider
About Sacrosidase
Sacrosidase (sold as Sucraid) was prescribed 1,517 times by 70 Medicare Part D providers in 2023, costing the program $18.5M. At $12K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 434 | Naloxone Hcl (Naloxone Hcl) | $19.0M | 232,875 |
| 435 | Elapegademase-Lvlr (Revcovi) | $19.0M | 52 |
| 436 | Methylprednisolone (Methylprednisolone) | $18.9M | 1,934,494 |
| 437 | Sacrosidase (Sucraid) | $18.5M | 1,517 |
| 438 | Enasidenib Mesylate (Idhifa) | $18.1M | 554 |
| 439 | Posaconazole (Posaconazole) | $18.0M | 7,163 |
| 440 | Metronidazole (Metronidazole) | $18.0M | 405,967 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology